Logo Logo
Hilfe
Hilfe
Switch Language to English

Lokerse, Wouter J. M.; Lazarian, Artur; Kleinhempel, Alisa; Petrini, Matteo; Schwarz, Patricia; Hossann, Martin; Holdt, Lesca M.; Mailänder, Volker und Lindner, Lars H. (2021): Mechanistic investigation of thermosensitive liposome immunogenicity and understanding the drivers for circulation half-life: A polyethylene glycol versus 1,2-dipalmitoyl-sn-glycero-3-phosphodiglycerol study. In: Journal of Controlled Release, Bd. 333: S. 1-15

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

Various thermosensitive liposome (TSL) formulations have been described to date and it is currently unclear which are optimal for solid tumor treatment. Sufficient circulation half-life is important and most liposomes obtain this by polyethylene glycol (PEG) surface modification. 1,2-dipalmitoyl-sn-glycero-3-phosphodiglycerol (DPPG(2)) has been described as a promising alternative which increases TSL circulation half-life and facilitates rapid drug release under mild hyperthermia at 20-30 mol%. The present work describes an investigation of the DPPG(2)-TSL protein corona, blood cell interactions, complement activation in human plasma/blood and hypersensitivity reactions in rats. Furthermore, accelerated blood clearance (ABC) was investigated to obtain a complete assessment of DPPG(2)-TSL interactions with components of the blood and identify drivers for circulation half-life. A higher mol% DPPG(2) increased Apolipoprotein E (ApoE) adsorption and decreased complement activation and granulocyte interaction in vitro. In contrast to PEG-TSL, DPPG(2)-TSL showed no ABC effect. In vivo hypersensitivity assessment by eicosanoid measurements, platelet and lymphocyte counting resembled the results of in vitro complement activation assays although here all DPPG(2)-TSL formulations induced hypersensitive responses upon i.v. administration. Prolonged circulation half-life of DPPG(2)-TSL may be ApoE-induced and the absent ABC effect demonstrates an advantage over PEG-TSL. Low complement activation in human plasma and blood for 20-30 mol% DPPG(2)-TSL presents a unique formulation attribute with the potential to strengthen clinical evaluation.

Dokument bearbeiten Dokument bearbeiten